5:45 PM
Oct 20, 2009
 |  BC Extra  |  Clinical News

Detailed data from HIV vaccine trial released

Additional data from the U.S. Army Surgeon General-sponsored, double-blind, Thai Phase III RV144 trial in 16,402 adult volunteers showed that ALVAC HIV vaccine from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) boosted by the AIDSVAX B/E gp120 vaccine missed the co-primary endpoints in the intent-to-treat (ITT) and per protocol...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >